Gardasil is a recombinant virus-like particle (VLP) vaccine. It does not contain any live, weakened, or killed virus. Instead, it uses lab-made protein shells that mimic the outer surface of human papillomavirus (HPV) closely enough to train the immune system, but carry no viral DNA and cannot cause infection. The current version, Gardasil 9, protects against nine HPV types and is the only HPV vaccine distributed in the United States.
How Virus-Like Particles Work
Traditional vaccines often use a weakened or inactivated version of the actual virus. That approach was problematic for HPV because the virus contains two genes that can cooperate to make human cells cancerous. Injecting any form of the intact virus, even a killed one, risked introducing those cancer-causing genes into patients. Researchers at the National Cancer Institute found a workaround: a single protein from the virus’s outer shell, called L1, could spontaneously snap together into hollow spheres that look almost identical to real HPV on the outside but are completely empty on the inside.
These hollow spheres are the virus-like particles. Each one is built from 72 five-sided clusters of the L1 protein, arranged in the same geometric pattern as a real HPV particle, with an average diameter of 50 to 60 nanometers. Because the shape so closely resembles the actual virus, the immune system mounts a strong response and produces antibodies that can block a real HPV infection. But because the particles contain no genetic material, there is zero chance of them replicating or causing disease.
How Gardasil Is Manufactured
The L1 proteins are produced using baker’s yeast (Saccharomyces cerevisiae), the same organism used in bread and beer. Separate batches of genetically engineered yeast are grown in carefully controlled fermentation tanks, each batch producing the L1 protein for one specific HPV type. Once the yeast cells have made enough protein, they’re broken open, and the released L1 proteins self-assemble into VLPs. Those particles are then purified through a series of chemical and physical steps before being combined into a single vaccine.
Because the vaccine is made in yeast rather than in eggs or animal cells, people with egg allergies are not at risk. However, anyone with a yeast allergy should flag that before vaccination. The final formulation also includes an aluminum-based compound (amorphous aluminum hydroxyphosphate sulfate) that acts as an adjuvant, a substance that amplifies the immune response so the body builds stronger, longer-lasting protection.
What Gardasil 9 Protects Against
Gardasil 9 targets nine HPV types: 6, 11, 16, 18, 31, 33, 45, 52, and 58. Types 16 and 18 are the most notorious, responsible for the majority of HPV-related cancers. Types 31, 33, 45, 52, and 58 account for a significant additional share of cervical, anal, and oropharyngeal cancers. Types 6 and 11 are lower-risk strains that cause roughly 90% of genital warts rather than cancer.
The FDA has approved Gardasil 9 for girls, boys, women, and men aged 9 through 45. In females, it is indicated for the prevention of cervical, vulvar, vaginal, anal, oropharyngeal, and other head and neck cancers, plus genital warts. In males, it covers anal cancer, oropharyngeal and other head and neck cancers, and genital warts.
Real-World Effectiveness
Clinical trials established Gardasil’s efficacy before licensure, and population-level data since then has been striking. Within 12 years of the vaccine’s introduction in the United States, infections with the four HPV types covered by the original Gardasil dropped 88% among females aged 14 to 19 and 81% among those aged 20 to 24. Cervical precancer rates fell in parallel: compared to 2008 and 2009, precancer among screened 18- to 20-year-olds was 50% lower by 2014 and 2015, and 36% lower among 21- to 24-year-olds. Among vaccinated women overall, the percentage of cervical lesions caused by vaccine-targeted HPV types has dropped by 40%.
These numbers reflect the earlier four-type version of Gardasil. Gardasil 9, which added five more cancer-causing strains, is expected to prevent an even larger share of HPV-related disease as vaccinated cohorts age into the years when these cancers typically develop.
How It Compares to Other Vaccine Types
Vaccines fall into several broad categories. Live-attenuated vaccines (like MMR) use a weakened form of the pathogen. Inactivated vaccines (like the flu shot) use a killed version. mRNA vaccines (like the COVID-19 vaccines from Pfizer and Moderna) deliver genetic instructions for cells to produce a viral protein temporarily. Gardasil fits into none of these categories. It belongs to the recombinant protein subunit class, specifically the VLP subclass, meaning it contains only a manufactured piece of the virus’s outer coat, pre-assembled into a particle shape, with no genetic material of any kind.
This design makes it one of the more straightforward vaccines in terms of safety profile. There is no live organism that could revert to a dangerous form, no viral DNA that could integrate into cells, and no mRNA that the body needs to translate. The immune system simply encounters a protein shell, learns to recognize it, and stands ready to neutralize the real virus if exposure occurs later.